Aragen Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 250.00 Cr
- Paid Up Capital ₹ 204.41 Cr
- Company Age 24 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 733.80 Cr
- Satisfied Charges ₹ 518.38 Cr
- Revenue Growth 26.17%
- Profit Growth 19.41%
- Ebitda 26.18%
- Net Worth 16.71%
- Total Assets 3.93%
About Aragen Life Sciences
Aragen Life Sciences Limited (ALSL) is a leading Public Limited Indian Non-Government Company incorporated in India on 07 December 2000 and has a history of 24 years and two months. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Gvk Biosciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 250.00 Cr and a paid-up capital of Rs 204.41 Cr.
The company currently has active open charges totaling ₹733.80 Cr. The company has closed loans amounting to ₹518.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Aragen Life Sciences Limited India are Sachin Dharap as Cfo, Ramakrishna Kasturi as Company Secretary, and Manmahesh Kantipudi as Ceo. Ajay Srivastava, Davinder Brar, Anita Ramachandran, and Four other members serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999TG2000PLC035826
- Company No.
035826
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Dec 2000
- Date of AGM
08 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Aragen Life Sciences Limited offer?
Aragen Life Sciences Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Product Development Research, Chemical Research Services, Research and Development (R&D) Work, Application Development Service, API Development Service, Custom Synthesis Service, Medicinal Chemistry Services, Business Planning and Management.
Who are the key members and board of directors at Aragen Life Sciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sachin Dharap | CFO | 25-Jan-2023 | Current |
Ramakrishna Kasturi  | Company Secretary | 07-Dec-2007 | Current |
| Manmahesh Kantipudi | CEO | 25-Jan-2023 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajat Sood | Director | 19-May-2021 | Current |
| Anita Ramachandran | Director | 07-Nov-2022 | Current |
| Ajay Srivastava | Director | 20-May-2021 | Current |
| Davinder Brar | Director | 26-Jul-2004 | Current |
| Manmahesh Kantipudi | Whole-Time Director | 29-May-2018 | Current |
| Gunapati Keshav | Director | 30-Jan-2020 | Current |
Financial Performance of Aragen Life Sciences.
Aragen Life Sciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.17% increase. The company also saw a substantial improvement in profitability, with a 19.41% increase in profit. The company's net worth Soared by an impressive increase of 16.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aragen Life Sciences?
In 2023, Aragen Life Sciences had a promoter holding of 67.41% and a public holding of 32.59%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Noveltech Feeds Private LimitedRajat Sood is a mutual person
Godrej And Boyce Manufacturing Company LimitedAnita Ramachandran is a mutual person
Blue Star LimitedAnita Ramachandran is a mutual person
Mountain Trail Foods Private LimitedDavinder Brar is a mutual person
Ujjivan Small Finance Bank LimitedAnita Ramachandran is a mutual person
Zeroharm Sciences Private LimitedManmahesh Kantipudi is a mutual person
Charges (Loans)
₹733.80 Cr
₹518.38 Cr
Charges Breakdown by Lending Institutions
- Others : 325.00 Cr
- Idbi Trusteeship Services Limited : 200.00 Cr
- Citi Bank N.A. : 151.80 Cr
- Yes Bank Limited : 57.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2024 | Others | ₹50.00 Cr | Open |
| 17 Aug 2023 | Citi Bank N.A. | ₹50.00 Cr | Open |
| 10 Feb 2022 | Idbi Trusteeship Services Limited | ₹200.00 Cr | Open |
| 07 Dec 2021 | Citi Bank N.A. | ₹50.00 Cr | Open |
| 08 Nov 2021 | Others | ₹100.00 Cr | Open |
How Many Employees Work at Aragen Life Sciences?
Aragen Life Sciences has a workforce of 3859 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aragen Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aragen Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
